| 12
 3
 4
 5
 6
 7
 8
 9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
 100
 101
 102
 103
 104
 105
 106
 107
 108
 109
 110
 111
 112
 113
 114
 115
 116
 117
 118
 119
 120
 121
 122
 123
 124
 125
 126
 127
 128
 129
 130
 131
 132
 133
 134
 135
 136
 137
 138
 139
 140
 141
 142
 143
 144
 145
 146
 147
 148
 149
 150
 151
 152
 153
 154
 155
 156
 157
 158
 159
 160
 161
 162
 163
 164
 165
 166
 167
 168
 169
 170
 171
 172
 173
 174
 175
 176
 177
 178
 179
 180
 181
 182
 183
 184
 185
 186
 187
 188
 189
 190
 191
 192
 193
 194
 195
 196
 197
 198
 199
 200
 201
 202
 203
 204
 205
 206
 207
 208
 209
 210
 211
 212
 213
 214
 215
 216
 217
 218
 219
 220
 221
 222
 223
 224
 225
 226
 227
 228
 229
 230
 231
 232
 233
 234
 235
 236
 237
 238
 239
 240
 241
 242
 243
 244
 245
 246
 247
 248
 249
 250
 251
 252
 253
 254
 255
 256
 257
 258
 259
 260
 261
 262
 263
 264
 265
 266
 267
 268
 269
 270
 271
 272
 273
 274
 275
 276
 277
 278
 279
 280
 281
 282
 283
 284
 285
 286
 287
 288
 289
 290
 291
 292
 293
 294
 295
 296
 297
 298
 299
 300
 301
 302
 303
 304
 305
 306
 307
 308
 309
 310
 311
 312
 313
 314
 315
 316
 317
 318
 319
 320
 321
 322
 323
 324
 325
 326
 327
 328
 329
 330
 331
 332
 333
 334
 335
 336
 337
 338
 339
 340
 341
 342
 343
 344
 345
 346
 347
 348
 349
 350
 351
 352
 353
 354
 355
 356
 357
 358
 359
 360
 361
 362
 363
 364
 365
 366
 367
 368
 369
 370
 371
 372
 373
 374
 375
 376
 377
 378
 379
 380
 381
 382
 383
 384
 385
 386
 387
 388
 389
 390
 391
 392
 393
 394
 395
 396
 397
 398
 399
 400
 401
 402
 403
 404
 405
 406
 407
 408
 409
 410
 411
 412
 413
 414
 415
 416
 417
 418
 419
 420
 421
 422
 423
 424
 425
 426
 427
 428
 429
 430
 431
 432
 433
 434
 435
 436
 437
 438
 439
 440
 441
 442
 443
 444
 445
 446
 447
 448
 449
 450
 451
 452
 453
 454
 455
 456
 457
 458
 459
 460
 461
 462
 463
 464
 465
 466
 467
 468
 469
 470
 471
 472
 473
 474
 475
 476
 477
 478
 479
 480
 481
 482
 483
 484
 485
 486
 487
 488
 489
 490
 491
 492
 493
 494
 495
 496
 497
 498
 499
 500
 501
 502
 503
 504
 505
 506
 507
 508
 509
 510
 511
 512
 513
 514
 515
 516
 517
 518
 519
 520
 521
 522
 523
 524
 525
 526
 527
 528
 529
 530
 531
 532
 533
 534
 535
 536
 537
 538
 539
 540
 541
 542
 543
 544
 545
 546
 547
 548
 549
 550
 551
 552
 553
 554
 555
 556
 557
 558
 559
 560
 561
 562
 563
 564
 565
 566
 567
 568
 569
 570
 571
 572
 573
 574
 575
 576
 577
 578
 579
 580
 581
 582
 583
 584
 585
 586
 587
 588
 589
 590
 591
 592
 593
 594
 595
 596
 597
 598
 599
 600
 601
 602
 
 | <?xml version="1.0" encoding="UTF-8"?>
<uniprot xmlns="http://uniprot.org/uniprot" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://uniprot.org/uniprot http://www.uniprot.org/support/docs/uniprot.xsd">
  <entry dataset="Swiss-Prot" created="2004-05-10" modified="2012-11-28" version="74">
    <accession>O44185</accession>
    <name>FLP13_CAEEL</name>
    <protein>
      <recommendedName>
        <fullName>FMRFamide-like neuropeptides 13</fullName>
      </recommendedName>
      <component>
        <recommendedName>
          <fullName>SDRPTRAMDSPLIRF-amide</fullName>
        </recommendedName>
      </component>
      <component>
        <recommendedName>
          <fullName>AMDSPLIRF-amide</fullName>
        </recommendedName>
      </component>
      <component>
        <recommendedName>
          <fullName>AADGAPLIRF-amide 1</fullName>
        </recommendedName>
      </component>
      <component>
        <recommendedName>
          <fullName>APEASPFIRF-amide 1</fullName>
        </recommendedName>
      </component>
      <component>
        <recommendedName>
          <fullName>AADGAPLIRF-amide 2</fullName>
        </recommendedName>
      </component>
      <component>
        <recommendedName>
          <fullName>APEASPFIRF-amide 2</fullName>
        </recommendedName>
      </component>
      <component>
        <recommendedName>
          <fullName>ASPSAPLIRF-amide</fullName>
        </recommendedName>
      </component>
      <component>
        <recommendedName>
          <fullName>SPSAVPLIRF-amide</fullName>
        </recommendedName>
      </component>
      <component>
        <recommendedName>
          <fullName>SAAAPLIRF-amide</fullName>
        </recommendedName>
      </component>
      <component>
        <recommendedName>
          <fullName>ASSAPLIRF-amide</fullName>
        </recommendedName>
      </component>
    </protein>
    <gene>
      <name type="primary">flp-13</name>
      <name type="ORF">F33D4.3</name>
    </gene>
    <organism>
      <name type="scientific">Caenorhabditis elegans</name>
      <dbReference type="NCBI Taxonomy" id="6239"/>
      <lineage>
        <taxon>Eukaryota</taxon>
        <taxon>Metazoa</taxon>
        <taxon>Ecdysozoa</taxon>
        <taxon>Nematoda</taxon>
        <taxon>Chromadorea</taxon>
        <taxon>Rhabditida</taxon>
        <taxon>Rhabditoidea</taxon>
        <taxon>Rhabditidae</taxon>
        <taxon>Peloderinae</taxon>
        <taxon>Caenorhabditis</taxon>
      </lineage>
    </organism>
    <reference key="1">
      <citation type="journal article" date="1998" name="Brain Res. Mol. Brain Res." volume="58" first="103" last="111">
        <title>FMRFamide-related gene family in the nematode, Caenorhabditis elegans.</title>
        <authorList>
          <person name="Nelson L.S."/>
          <person name="Kim K."/>
          <person name="Memmott J.E."/>
          <person name="Li C."/>
        </authorList>
        <dbReference type="MEDLINE" id="98352130"/>
        <dbReference type="PubMed" id="9685599"/>
        <dbReference type="DOI" id="10.1016/S0169-328X(98)00106-5"/>
      </citation>
      <scope>NUCLEOTIDE SEQUENCE [MRNA]</scope>
      <scope>DEVELOPMENTAL STAGE</scope>
      <source>
        <strain>Bristol N2</strain>
      </source>
    </reference>
    <reference key="2">
      <citation type="journal article" date="1998" name="Science" volume="282" first="2012" last="2018">
        <title>Genome sequence of the nematode C. elegans: a platform for investigating biology.</title>
        <authorList>
          <consortium name="The C. elegans sequencing consortium"/>
        </authorList>
        <dbReference type="MEDLINE" id="99069613"/>
        <dbReference type="PubMed" id="9851916"/>
        <dbReference type="DOI" id="10.1126/science.282.5396.2012"/>
      </citation>
      <scope>NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]</scope>
      <source>
        <strain>Bristol N2</strain>
      </source>
    </reference>
    <reference key="3">
      <citation type="journal article" date="2005" name="Biochem. Biophys. Res. Commun." volume="335" first="76" last="86">
        <title>Discovering neuropeptides in Caenorhabditis elegans by two dimensional liquid chromatography and mass spectrometry.</title>
        <authorList>
          <person name="Husson S.J."/>
          <person name="Clynen E."/>
          <person name="Baggerman G."/>
          <person name="De Loof A."/>
          <person name="Schoofs L."/>
        </authorList>
        <dbReference type="PubMed" id="16061202"/>
        <dbReference type="DOI" id="10.1016/j.bbrc.2005.07.044"/>
      </citation>
      <scope>PROTEIN SEQUENCE OF 52-60; 64-73; 76-85; 89-98; 101-110; 114-123; 126-135 AND 138-146</scope>
      <scope>AMIDATION AT PHE-60; PHE-73; PHE-85; PHE-98; PHE-110; PHE-123; PHE-135 AND PHE-146</scope>
      <source>
        <strain>Bristol N2</strain>
      </source>
    </reference>
    <reference key="4">
      <citation type="journal article" date="2001" name="Biochem. Biophys. Res. Commun." volume="286" first="1170" last="1176">
        <title>Isolation and preliminary biological assessment of AADGAPLIRFamide and SVPGVLRFamide from Caenorhabditis elegans.</title>
        <authorList>
          <person name="Marks N.J."/>
          <person name="Shaw C."/>
          <person name="Halton D.W."/>
          <person name="Thompson D.P."/>
          <person name="Geary T.G."/>
          <person name="Li C."/>
          <person name="Maule A.G."/>
        </authorList>
        <dbReference type="MEDLINE" id="21418823"/>
        <dbReference type="PubMed" id="11527423"/>
        <dbReference type="DOI" id="10.1006/bbrc.2001.5524"/>
      </citation>
      <scope>PROTEIN SEQUENCE OF 64-73 AND 89-98</scope>
      <scope>FUNCTION</scope>
      <scope>MASS SPECTROMETRY</scope>
      <scope>AMIDATION AT PHE-73 AND PHE-98</scope>
    </reference>
    <reference key="5">
      <citation type="journal article" date="1997" name="Biochem. Biophys. Res. Commun." volume="231" first="591" last="595">
        <title>APEASPFIRFamide, a novel FMRFamide-related decapeptide from Caenorhabditis elegans: structure and myoactivity.</title>
        <authorList>
          <person name="Marks N.J."/>
          <person name="Maule A.G."/>
          <person name="Geary T.G."/>
          <person name="Thompson D.P."/>
          <person name="Davis J.P."/>
          <person name="Halton D.W."/>
          <person name="Verhaert P."/>
          <person name="Shaw C."/>
        </authorList>
        <dbReference type="PubMed" id="9070852"/>
        <dbReference type="DOI" id="10.1006/bbrc.1997.6155"/>
      </citation>
      <scope>PROTEIN SEQUENCE OF 76-85 AND 101-110</scope>
      <scope>FUNCTION</scope>
      <scope>MASS SPECTROMETRY</scope>
      <scope>AMIDATION AT PHE-85 AND PHE-110</scope>
    </reference>
    <reference key="6">
      <citation type="journal article" date="2004" name="J. Comp. Neurol." volume="475" first="540" last="550">
        <title>Expression and regulation of an FMRFamide-related neuropeptide gene family in Caenorhabditis elegans.</title>
        <authorList>
          <person name="Kim K."/>
          <person name="Li C."/>
        </authorList>
        <dbReference type="PubMed" id="15236235"/>
        <dbReference type="DOI" id="10.1002/cne.20189"/>
      </citation>
      <scope>TISSUE SPECIFICITY</scope>
      <scope>DEVELOPMENTAL STAGE</scope>
    </reference>
    <reference key="7">
      <citation type="journal article" date="2005" name="J. Neurobiol." volume="65" first="304" last="319">
        <title>Role of a FMRFamide-like family of neuropeptides in the pharyngeal nervous system of Caenorhabditis elegans.</title>
        <authorList>
          <person name="Papaioannou S."/>
          <person name="Marsden D."/>
          <person name="Franks C.J."/>
          <person name="Walker R.J."/>
          <person name="Holden-Dye L."/>
        </authorList>
        <dbReference type="PubMed" id="16187307"/>
        <dbReference type="DOI" id="10.1002/neu.20201"/>
      </citation>
      <scope>FUNCTION</scope>
    </reference>
    <comment type="function">
      <text evidence="1 2 3">FMRFamides and FMRFamide-like peptides are neuropeptides. AADGAPLIRF-amide and APEASPFIRF-amide inhibit muscle tension in somatic muscle. APEASPFIRF-amide is a potent inhibitor of the activity of dissected pharyngeal myogenic muscle system.</text>
    </comment>
    <comment type="subcellular location">
      <subcellularLocation>
        <location>Secreted</location>
      </subcellularLocation>
    </comment>
    <comment type="tissue specificity">
      <text evidence="4">Each flp gene is expressed in a distinct set of neurons. Flp-13 is expressed in the ASE sensory neurons, the DD motor neurons, the 15, M3 and M5 cholinergic pharyngeal motoneurons, and the ASG, ASK and BAG neurons.</text>
    </comment>
    <comment type="developmental stage">
      <text evidence="4 5">Expressed from the comma stage of embryogenesis, during all larval stages, and in low levels in adults.</text>
    </comment>
    <comment type="mass spectrometry" mass="1032" method="MALDI" evidence="1">
      <location>
        <begin position="64"/>
        <end position="73"/>
      </location>
      <location>
        <begin position="89"/>
        <end position="98"/>
      </location>
      <text>The measured mass is that of either AADGAPLIRF-amide 1 or AADGAPLIRF-amide 2.</text>
    </comment>
    <comment type="mass spectrometry" mass="1133.7" method="MALDI" evidence="2">
      <location>
        <begin position="76"/>
        <end position="85"/>
      </location>
      <location>
        <begin position="101"/>
        <end position="110"/>
      </location>
    </comment>
    <comment type="similarity">
      <text>Belongs to the FARP (FMRFamide related peptide) family.</text>
    </comment>
    <!-- These elements were obtained from accession Q00955 -->
    <comment type="catalytic activity">
      <text>ATP + acetyl-CoA + HCO(3)(-) = ADP + phosphate + malonyl-CoA.</text>
    </comment>
    <comment type="catalytic activity">
      <text>ATP + biotin-[carboxyl-carrier-protein] + CO(2) = ADP + phosphate + carboxy-biotin-[carboxyl-carrier-protein].</text>
    </comment>
    <comment type="cofactor">
      <text>Biotin (By similarity).</text>
    </comment>
    <comment type="cofactor">
      <text>Binds 2 manganese ions per subunit (By similarity).</text>
    </comment>
    <comment type="enzyme regulation">
      <text evidence="6">By phosphorylation. The catalytic activity is inhibited by soraphen A, a polyketide isolated from the myxobacterium Sorangium cellulosum and a potent inhibitor of fungal growth.</text>
    </comment>
    <comment type="pathway">
      <text>Lipid metabolism; malonyl-CoA biosynthesis; malonyl-CoA from acetyl-CoA: step 1/1.</text>
    </comment>
    <comment type="subunit">
      <text evidence="7 8 9">Homodimer.</text>
    </comment>
    <comment type="induction">
      <text evidence="6 11 12 13">Repressed in presence of fatty acids. Repressed 3-fold by lipid precursors, inositol and choline, and also controlled by regulatory factors INO2, INO4 and OPI1.</text>
    </comment>
    <comment type="miscellaneous">
      <text>Present with 20200 molecules/cell in log phase SD medium.</text>
    </comment>
    <!-- These elements were obtained from accession Q8W1X2 -->
    <comment type="biophysicochemical properties">
      <kinetics>
        <KM>98 uM for ATP</KM>
        <KM>688 uM for pyridoxal</KM>
        <Vmax>1.604 mmol/min/mg enzyme</Vmax>
      </kinetics>
      <phDependence>Optimum pH is 6.0. Active from pH 4.5 to 10.5.</phDependence>
    </comment>
    <comment type="alternative products">
      <event type="alternative splicing"/>
      <isoform>
        <id>Q8W1X2-1</id>
        <name>1</name>
        <sequence type="displayed"/>
      </isoform>
      <isoform>
        <id>Q8W1X2-2</id>
        <name>2</name>
        <sequence type="described" ref="VSP_004654"/>
        <note>No experimental confirmation available.</note>
      </isoform>
    </comment>
    <!-- These elements were obtained from accession Q9BZZ5 -->
    <comment type="domain">
      <text>Two regions, an N-terminal (aa 96-107) and a C-terminal (aa 274-311) are required for binding FGF2.</text>
    </comment>
    <comment type="PTM">
      <text>Acetylation at Lys-251 impairs antiapoptotic function.</text>
    </comment>
    <comment type="sequence caution">
      <conflict type="erroneous initiation">
        <sequence resource="EMBL-CDS" id="AAB86528" version="1"/>
      </conflict>
      <text>Translation N-terminally shortened.</text>
    </comment>
    <comment type="sequence caution">
      <conflict type="frameshift">
        <sequence resource="EMBL-CDS" id="AAB86528" version="1"/>
      </conflict>
    </comment>
    <comment type="online information" name="NIEHS-SNPs">
      <link uri="http://egp.gs.washington.edu/data/api5/"/>
    </comment>
    <!-- These elements were obtained from accession P28355 -->
    <comment type="RNA editing">
      <location>
        <position position="156"/>
      </location>
      <location>
        <position position="158"/>
      </location>
      <location>
        <position position="160"/>
      </location>
      <text evidence="4">Partially edited. RNA editing generates receptor isoforms that differ in their ability to interact with the phospholipase C signaling cascade in a transfected cell line, suggesting that this RNA processing event may contribute to the modulation of serotonergic neurotransmission in the central nervous system.</text>
    </comment>
    <comment type="polymorphism">
      <text>Position 23 is polymorphic; the frequencies in unrelated Caucasians are 0.87 for Cys and 0.13 for Ser.</text>
    </comment>
    <!-- These elements were obtained from accession Q01718 -->
    <comment type="disease">
      <text evidence="2 3 4 5 6">Defects in MC2R are the cause of glucocorticoid deficiency type 1 (GCCD1) [MIM:202200]; also known as familial glucocorticoid deficiency type 1 (FGD1). GCCD1 is an autosomal recessive disorder due to congenital insensitivity or resistance to adrenocorticotropin (ACTH). It is characterized by progressive primary adrenal insufficiency, without mineralocorticoid deficiency.</text>
    </comment>
    <!-- These elements were obtained from accession P11911 -->
    <comment type="disruption phenotype">
      <text evidence="8">Mice display impaired B-cell development which does not progress pass the progenitor stage.</text>
    </comment>
    <!-- These elements were obtained from accession Q06811 -->
    <comment type="allergen">
      <text>Causes an allergic reaction in human.</text>
    </comment>
    <!-- These elements were obtained from accession P55902 -->
    <comment type="toxic dose">
      <text evidence="1">LD(50) is 50 ug/kg in mouse by intracerebroventricular injection and 600 ng/g in Blatella germanica.</text>
    </comment>
    <!-- These elements were obtained from accession P42212 -->
    <comment type="biotechnology">
      <text evidence="1">Green fluorescent protein has been engineered to produce a vast number of variously colored mutants, fusion proteins, and biosensors. Fluorescent proteins and its mutated allelic forms, blue, cyan and yellow have become a useful and ubiquitous tool for making chimeric proteins, where they function as a fluorescent protein tag. Typically they tolerate N- and C-terminal fusion to a broad variety of proteins. They have been expressed in most known cell types and are used as a noninvasive fluorescent marker in living cells and organisms. They enable a wide range of applications where they have functioned as a cell lineage tracer, reporter of gene expression, or as a measure of protein-protein interactions.</text>
    </comment>
    <comment type="biotechnology">
      <text evidence="1">Can also be used as a molecular thermometer, allowing accurate temperature measurements in fluids. The measurement process relies on the detection of the blinking of GFP using fluorescence correlation spectroscopy.</text>
    </comment>
    <!-- These elements were obtained from accession O14543 -->
    <comment type="pharmaceutical">
      <text>Could be used as a possible therapeutic agent for treating rheumatoid arthritis.</text>
    </comment>
    <!-- These elements were obtained from accession P40939 -->
    <comment type="interaction">
      <interactant intactId="EBI-356720"/>
      <interactant intactId="EBI-746969">
        <id>Q9H0R8</id>
        <label>GABARAPL1</label>
      </interactant>
      <organismsDiffer>false</organismsDiffer>
      <experiments>4</experiments>
    </comment>
    <comment type="interaction">
      <interactant intactId="EBI-356720"/>
      <interactant intactId="EBI-720116">
        <id>P60520</id>
        <label>GABARAPL2</label>
      </interactant>
      <organismsDiffer>false</organismsDiffer>
      <experiments>3</experiments>
    </comment>
    <!-- These elements were obtained from accession A6NMY6 -->
    <comment type="caution">
      <text>Could be the product of a pseudogene. The existence of a transcript at this locus is supported by only one sequence submission (PubMed:2174397).</text>
    </comment>
    <dbReference type="EMBL" id="AF042400">
      <property type="protein sequence ID" value="AAC08951.1"/>
      <property type="molecule type" value="mRNA"/>
    </dbReference>
    <dbReference type="EMBL" id="FO080445">
      <property type="protein sequence ID" value="CCD63768.1"/>
      <property type="molecule type" value="Genomic_DNA"/>
    </dbReference>
    <dbReference type="PIR" id="T32553">
      <property type="entry name" value="T32553"/>
    </dbReference>
    <dbReference type="RefSeq" id="NP_501255.1">
      <property type="nucleotide sequence ID" value="NM_068854.1"/>
    </dbReference>
    <dbReference type="UniGene" id="Cel.58"/>
    <dbReference type="ProteinModelPortal" id="O44185"/>
    <dbReference type="STRING" id="O44185"/>
    <dbReference type="EnsemblMetazoa" id="F33D4.3">
      <property type="protein sequence ID" value="F33D4.3"/>
      <property type="gene ID" value="F33D4.3"/>
    </dbReference>
    <dbReference type="GeneID" id="177547"/>
    <dbReference type="KEGG" id="cel:CELE_F33D4.3"/>
    <dbReference type="UCSC" id="F33D4.3">
      <property type="organism name" value="c. elegans"/>
    </dbReference>
    <dbReference type="CTD" id="177547"/>
    <dbReference type="WormBase" id="F33D4.3">
      <property type="protein sequence ID" value="CE17033"/>
      <property type="gene ID" value="WBGene00001456"/>
      <property type="gene designation" value="flp-13"/>
    </dbReference>
    <dbReference type="eggNOG" id="NOG70956"/>
    <dbReference type="GeneTree" id="ENSGT00570000079955"/>
    <dbReference type="HOGENOM" id="HOG000018010"/>
    <dbReference type="InParanoid" id="O44185"/>
    <dbReference type="OMA" id="VAIQAFD"/>
    <dbReference type="NextBio" id="897310"/>
    <dbReference type="ArrayExpress" id="O44185"/>
    <dbReference type="GO" id="GO:0005576">
      <property type="term" value="C:extracellular region"/>
      <property type="evidence" value="IC:UniProtKB"/>
    </dbReference>
    <dbReference type="GO" id="GO:0007218">
      <property type="term" value="P:neuropeptide signaling pathway"/>
      <property type="evidence" value="IDA:UniProtKB"/>
    </dbReference>
    <dbReference type="InterPro" id="IPR002544">
      <property type="entry name" value="FMRFamid-related_peptide-like"/>
    </dbReference>
    <dbReference type="Pfam" id="PF01581">
      <property type="entry name" value="FARP"/>
      <property type="match status" value="9"/>
    </dbReference>
    <proteinExistence type="evidence at protein level"/>
    <keyword id="KW-0027">Amidation</keyword>
    <keyword id="KW-0165">Cleavage on pair of basic residues</keyword>
    <keyword id="KW-0181">Complete proteome</keyword>
    <keyword id="KW-0903">Direct protein sequencing</keyword>
    <keyword id="KW-0527">Neuropeptide</keyword>
    <keyword id="KW-1185">Reference proteome</keyword>
    <keyword id="KW-0677">Repeat</keyword>
    <keyword id="KW-0964">Secreted</keyword>
    <keyword id="KW-0732">Signal</keyword>
    <feature type="signal peptide" status="potential">
      <location>
        <begin position="1"/>
        <end position="17"/>
      </location>
    </feature>
    <feature type="propeptide" status="potential" id="PRO_0000009556" evidence="7">
      <location>
        <begin position="18"/>
        <end position="43"/>
      </location>
    </feature>
    <feature type="peptide" description="SDRPTRAMDSPLIRF-amide" status="potential" id="PRO_0000248047" evidence="5">
      <location>
        <begin position="46"/>
        <end position="60"/>
      </location>
    </feature>
    <feature type="peptide" description="AMDSPLIRF-amide" id="PRO_0000311849" evidence="6">
      <location>
        <begin position="52"/>
        <end position="60"/>
      </location>
    </feature>
    <feature type="peptide" description="AADGAPLIRF-amide 1" id="PRO_0000009557" evidence="1 6">
      <location>
        <begin position="64"/>
        <end position="73"/>
      </location>
    </feature>
    <feature type="peptide" description="APEASPFIRF-amide 1" id="PRO_0000009558" evidence="2 6">
      <location>
        <begin position="76"/>
        <end position="85"/>
      </location>
    </feature>
    <feature type="peptide" description="AADGAPLIRF-amide 2" id="PRO_0000009559" evidence="1 6">
      <location>
        <begin position="89"/>
        <end position="98"/>
      </location>
    </feature>
    <feature type="peptide" description="APEASPFIRF-amide 2" id="PRO_0000248048" evidence="2 6">
      <location>
        <begin position="101"/>
        <end position="110"/>
      </location>
    </feature>
    <feature type="peptide" description="ASPSAPLIRF-amide" id="PRO_0000248049" evidence="6">
      <location>
        <begin position="114"/>
        <end position="123"/>
      </location>
    </feature>
    <feature type="peptide" description="SPSAVPLIRF-amide" id="PRO_0000248050" evidence="6">
      <location>
        <begin position="126"/>
        <end position="135"/>
      </location>
    </feature>
    <feature type="peptide" description="SAAAPLIRF-amide" id="PRO_0000248051" evidence="6">
      <location>
        <begin position="138"/>
        <end position="146"/>
      </location>
    </feature>
    <feature type="peptide" description="ASSAPLIRF-amide" status="potential" id="PRO_0000248052" evidence="5">
      <location>
        <begin position="149"/>
        <end position="157"/>
      </location>
    </feature>
    <feature type="modified residue" description="Phenylalanine amide" evidence="6">
      <location>
        <position position="60"/>
      </location>
    </feature>
    <feature type="modified residue" description="Phenylalanine amide" evidence="1 6">
      <location>
        <position position="73"/>
      </location>
    </feature>
    <feature type="modified residue" description="Phenylalanine amide" evidence="2 6">
      <location>
        <position position="85"/>
      </location>
    </feature>
    <feature type="modified residue" description="Phenylalanine amide" evidence="1 6">
      <location>
        <position position="98"/>
      </location>
    </feature>
    <feature type="modified residue" description="Phenylalanine amide" evidence="2 6">
      <location>
        <position position="110"/>
      </location>
    </feature>
    <feature type="modified residue" description="Phenylalanine amide" evidence="6">
      <location>
        <position position="123"/>
      </location>
    </feature>
    <feature type="modified residue" description="Phenylalanine amide" evidence="6">
      <location>
        <position position="135"/>
      </location>
    </feature>
    <feature type="modified residue" description="Phenylalanine amide" evidence="6">
      <location>
        <position position="146"/>
      </location>
    </feature>
    <feature type="modified residue" description="Phenylalanine amide" status="potential" evidence="5">
      <location>
        <position position="157"/>
      </location>
    </feature>
    <evidence key="1" type="ECO:0000006">
      <source>
        <dbReference type="PubMed" id="11527423"/>
      </source>
    </evidence>
    <evidence key="2" type="ECO:0000006">
      <source>
        <dbReference type="PubMed" id="9070852"/>
      </source>
    </evidence>
    <evidence key="3" type="ECO:0000006">
      <source>
        <dbReference type="PubMed" id="16187307"/>
      </source>
    </evidence>
    <evidence key="4" type="ECO:0000006">
      <source>
        <dbReference type="PubMed" id="15236235"/>
      </source>
    </evidence>
    <evidence key="5" type="ECO:0000006">
      <source>
        <dbReference type="PubMed" id="9685599"/>
      </source>
    </evidence>
    <evidence key="6" type="ECO:0000006">
      <source>
        <dbReference type="PubMed" id="16061202"/>
      </source>
    </evidence>
    <evidence key="7" type="ECO:0000001"/>
    <sequence length="160" mass="17736" checksum="BE4C24E9B85FCD11" modified="1998-06-01" version="1" precursor="true">
MMTSLLTISMFVVAIQAFDSSEIRMLDEQYDTKNPFFQFLENSKRSDRPTRAMDSPLIRF
GKRAADGAPLIRFGRAPEASPFIRFGKRAADGAPLIRFGRAPEASPFIRFGKRASPSAPL
IRFGRSPSAVPLIRFGRSAAAPLIRFGRASSAPLIRFGRK
</sequence>
  </entry>
  <copyright>
    Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
    Distributed under the Creative Commons Attribution-NoDerivs License
  </copyright>
</uniprot>
 |